These results of proteomics, gene and protein expressions allow to elect HSPB1 as a predictive factor of tumor aggressiveness in a restricted set of GBM cases, and it may worth further exploration as a potential therapeutic target for these specific cases. Here, HSPB1 is linked to neoplasm.